Sarepta Therapeutics, Inc.
SRPT
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.4B
$22.50
▼ -2.13%
P/E
7.26
Mkt Cap
$2.4B
52-Wk Range
$14.68–$25.32
52-Week Range
$14.68 - $25.32
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 27.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.2).
Growth
Strong growth ahead
Value
Deep value opportunity - significant discount to sector peers
Momentum
Hot
+44.7% over 3m
Quality
Strong
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying SRPT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 2, 2026
AUG 5, 2026
Reported EPS of -$0.05 vs $0.22 consensus (-123.0% surprise). Revenue of $401.3M vs $366.4M expected (+9.5%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-123.0%
Revenue trend · last 2Q
—
-34%
Q1 26
Q2 26
$730.8M
$401.3M
Margins · last 2Q
Gross
0.0%
Operating
3.3%
Profit
-1.2%
Wall Street consensus
6 analysts · 67% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
67%
Hold
0%
Sell
33%
Median Price Target
—
Latest: HC Wainwright · Jul 28, 2026
vs Industry
How SRPT stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.